The Experts below are selected from a list of 2664 Experts worldwide ranked by ideXlab platform
Nicolas C Issa - One of the best experts on this subject based on the ideXlab platform.
-
live attenuated Varicella Zoster Vaccine in hematopoietic stem cell transplantation recipients
Biology of Blood and Marrow Transplantation, 2014Co-Authors: Nicolas C Issa, Francisco M Marty, Houry Leblebjian, Alicia Galar, Margaret M Shea, Joseph H Antin, Robert J SoifferAbstract:Hematopoietic stem cell transplantation (HSCT) recipients are at risk for Varicella-Zoster virus (VZV) reactivation. Vaccination may help restore VZV immunity; however, the available live attenuated VZV Vaccine (Zostavax) is contraindicated in immunocompromised hosts. We report our experience with using a single dose of VZV Vaccine in 110 adult autologous and allogeneic HSCT recipients who were about 2 years after transplantation, free of graft-versus-host disease, and not receiving immunosuppression. One hundred eight Vaccine recipients (98.2%) had no clinically apparent adverse events with a median follow-up period of 9.5 months (interquartile range, 6 to 16; range, 2 to 28). Two Vaccine recipients (1.8%) developed a skin rash (one Zoster-like rash with associated pain, one Varicella-like) within 42 days post-vaccination that resolved with antiviral therapy. We could not confirm if these rashes were due to Vaccine (Oka) or wild-type VZV. No other possible cases of VZV reactivation have occurred with about 1178 months of follow-up. Live attenuated Zoster Vaccine appears generally safe in this population when vaccinated as noted; the overall vaccination risk needs to be weighed against the risk of wild-type VZV disease in this high-risk population.
Naoshi Ota - One of the best experts on this subject based on the ideXlab platform.
-
Safety of live attenuated Varicella-Zoster Vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study
BMC Infectious Diseases, 2019Co-Authors: Satoko Ohfuji, Kazuya Ito, Megumi Inoue, Motoki Ishibashi, Hiroko Kumashiro, Yoshio Hirota, Eiji Kayano, Naoshi OtaAbstract:Background In Japan, freeze-dried live attenuated Varicella-Zoster Vaccine is available for adults aged ≥50 years to prevent herpes Zoster. However, limited evidence has been accumulated regarding Vaccine safety for patients with underlying illnesses, who have been considered as the high-risk group for herpes Zoster. Methods A prospective cohort study of 1200 healthy adults and 300 patients with underlying illnesses such as malignancy, diabetes mellitus, autoimmune diseases, and renal diseases was conducted. All subjects were vaccinated and then their adverse events (AEs) were followed for 28 days after vaccination. Key safety measures included any AEs, severe AEs (SAEs), and Vaccine-related AEs such as injection-site AEs and systemic AEs. The frequencies and 95% confidence intervals of AEs were calculated. Results During the follow-up period, 2 SAEs (bone fracture and acute cholecystitis) among healthy adults and 1 SAE (disseminated mycobacteriosis) among patients with underlying illnesses were reported, although none of them was diagnosed as Vaccine-related. Vaccine-related AEs were reported in 42% of healthy adults and patients with underlying illnesses, and the proportions were similar between the groups. The most frequent AEs were injection-site AEs in both groups (i.e., 41 and 39%), and systemic AEs were observed in 4% of both groups. Only among healthy adults, those with a history of herpes Zoster were more likely to report injection-site AEs than those without a history of herpes Zoster (53% vs 39%). Conclusions The present study confirmed the safety of freeze-dried, live attenuated Varicella-Zoster Vaccine even in patients with underlying illnesses. A history of herpes Zoster might be related to development of injection-site AEs in healthy adults. Trial registration The study was prospectively registered on Japic-Clinical Trials Information as JapicCTI-163415 on October 31, 2016.
-
Safety of live attenuated Varicella-Zoster Vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study.
BMC infectious diseases, 2019Co-Authors: Satoko Ohfuji, Kazuya Ito, Megumi Inoue, Motoki Ishibashi, Hiroko Kumashiro, Yoshio Hirota, Eiji Kayano, Naoshi OtaAbstract:In Japan, freeze-dried live attenuated Varicella-Zoster Vaccine is available for adults aged ≥50 years to prevent herpes Zoster. However, limited evidence has been accumulated regarding Vaccine safety for patients with underlying illnesses, who have been considered as the high-risk group for herpes Zoster. A prospective cohort study of 1200 healthy adults and 300 patients with underlying illnesses such as malignancy, diabetes mellitus, autoimmune diseases, and renal diseases was conducted. All subjects were vaccinated and then their adverse events (AEs) were followed for 28 days after vaccination. Key safety measures included any AEs, severe AEs (SAEs), and Vaccine-related AEs such as injection-site AEs and systemic AEs. The frequencies and 95% confidence intervals of AEs were calculated. During the follow-up period, 2 SAEs (bone fracture and acute cholecystitis) among healthy adults and 1 SAE (disseminated mycobacteriosis) among patients with underlying illnesses were reported, although none of them was diagnosed as Vaccine-related. Vaccine-related AEs were reported in 42% of healthy adults and patients with underlying illnesses, and the proportions were similar between the groups. The most frequent AEs were injection-site AEs in both groups (i.e., 41 and 39%), and systemic AEs were observed in 4% of both groups. Only among healthy adults, those with a history of herpes Zoster were more likely to report injection-site AEs than those without a history of herpes Zoster (53% vs 39%). The present study confirmed the safety of freeze-dried, live attenuated Varicella-Zoster Vaccine even in patients with underlying illnesses. A history of herpes Zoster might be related to development of injection-site AEs in healthy adults. The study was prospectively registered on Japic-Clinical Trials Information as JapicCTI-163415 on October 31, 2016.
Robert J Soiffer - One of the best experts on this subject based on the ideXlab platform.
-
live attenuated Varicella Zoster Vaccine in hematopoietic stem cell transplantation recipients
Biology of Blood and Marrow Transplantation, 2014Co-Authors: Nicolas C Issa, Francisco M Marty, Houry Leblebjian, Alicia Galar, Margaret M Shea, Joseph H Antin, Robert J SoifferAbstract:Hematopoietic stem cell transplantation (HSCT) recipients are at risk for Varicella-Zoster virus (VZV) reactivation. Vaccination may help restore VZV immunity; however, the available live attenuated VZV Vaccine (Zostavax) is contraindicated in immunocompromised hosts. We report our experience with using a single dose of VZV Vaccine in 110 adult autologous and allogeneic HSCT recipients who were about 2 years after transplantation, free of graft-versus-host disease, and not receiving immunosuppression. One hundred eight Vaccine recipients (98.2%) had no clinically apparent adverse events with a median follow-up period of 9.5 months (interquartile range, 6 to 16; range, 2 to 28). Two Vaccine recipients (1.8%) developed a skin rash (one Zoster-like rash with associated pain, one Varicella-like) within 42 days post-vaccination that resolved with antiviral therapy. We could not confirm if these rashes were due to Vaccine (Oka) or wild-type VZV. No other possible cases of VZV reactivation have occurred with about 1178 months of follow-up. Live attenuated Zoster Vaccine appears generally safe in this population when vaccinated as noted; the overall vaccination risk needs to be weighed against the risk of wild-type VZV disease in this high-risk population.
Francisco M Marty - One of the best experts on this subject based on the ideXlab platform.
-
live attenuated Varicella Zoster Vaccine in hematopoietic stem cell transplantation recipients
Biology of Blood and Marrow Transplantation, 2014Co-Authors: Nicolas C Issa, Francisco M Marty, Houry Leblebjian, Alicia Galar, Margaret M Shea, Joseph H Antin, Robert J SoifferAbstract:Hematopoietic stem cell transplantation (HSCT) recipients are at risk for Varicella-Zoster virus (VZV) reactivation. Vaccination may help restore VZV immunity; however, the available live attenuated VZV Vaccine (Zostavax) is contraindicated in immunocompromised hosts. We report our experience with using a single dose of VZV Vaccine in 110 adult autologous and allogeneic HSCT recipients who were about 2 years after transplantation, free of graft-versus-host disease, and not receiving immunosuppression. One hundred eight Vaccine recipients (98.2%) had no clinically apparent adverse events with a median follow-up period of 9.5 months (interquartile range, 6 to 16; range, 2 to 28). Two Vaccine recipients (1.8%) developed a skin rash (one Zoster-like rash with associated pain, one Varicella-like) within 42 days post-vaccination that resolved with antiviral therapy. We could not confirm if these rashes were due to Vaccine (Oka) or wild-type VZV. No other possible cases of VZV reactivation have occurred with about 1178 months of follow-up. Live attenuated Zoster Vaccine appears generally safe in this population when vaccinated as noted; the overall vaccination risk needs to be weighed against the risk of wild-type VZV disease in this high-risk population.
Alicia Galar - One of the best experts on this subject based on the ideXlab platform.
-
live attenuated Varicella Zoster Vaccine in hematopoietic stem cell transplantation recipients
Biology of Blood and Marrow Transplantation, 2014Co-Authors: Nicolas C Issa, Francisco M Marty, Houry Leblebjian, Alicia Galar, Margaret M Shea, Joseph H Antin, Robert J SoifferAbstract:Hematopoietic stem cell transplantation (HSCT) recipients are at risk for Varicella-Zoster virus (VZV) reactivation. Vaccination may help restore VZV immunity; however, the available live attenuated VZV Vaccine (Zostavax) is contraindicated in immunocompromised hosts. We report our experience with using a single dose of VZV Vaccine in 110 adult autologous and allogeneic HSCT recipients who were about 2 years after transplantation, free of graft-versus-host disease, and not receiving immunosuppression. One hundred eight Vaccine recipients (98.2%) had no clinically apparent adverse events with a median follow-up period of 9.5 months (interquartile range, 6 to 16; range, 2 to 28). Two Vaccine recipients (1.8%) developed a skin rash (one Zoster-like rash with associated pain, one Varicella-like) within 42 days post-vaccination that resolved with antiviral therapy. We could not confirm if these rashes were due to Vaccine (Oka) or wild-type VZV. No other possible cases of VZV reactivation have occurred with about 1178 months of follow-up. Live attenuated Zoster Vaccine appears generally safe in this population when vaccinated as noted; the overall vaccination risk needs to be weighed against the risk of wild-type VZV disease in this high-risk population.
